Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.

ABSTRACT:

Importance

Current data are lacking regarding the risk of biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) use on the development of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).

Objective

To determine the risk of developing ILD in patients with RA undergoing treatment with different b/tsDMARDs.

Design, setting, and participants

Retrospective cohort study using claims data from the Optum Clinformatics Data Mart between December 2003 and December 2019. Adult patients with RA, 1 year or more of continuous enrollment, treatment with a b/tsDMARD of interest, and without preexisting ILD were included. Data were analyzed from October 2021 to April 2022.

Exposures

New administration of adalimumab, abatacept

SUBMITTER: Baker MC 

PROVIDER: S-EPMC10028485 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature